A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer

Katsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki, Kadoaki Oohashi, Kiichiro Ninomiya, Eiki Ichihara, Toshio Kubo, Takashi Ninomiya, Kenichi Chikamori, Daijiro Harada, Naoyuki Nogami, Taizo Hirata, Shiro Hinotsu, Shinichi Toyooka, Katsuyuki Kiura

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Trastuzumab emtansine (T-DM1), an anti-erb-b2 receptor tyrosine kinase 2 (HER2) antibody-drug conjugate, has been shown to significantly improve survival in HER2-positive breast cancer. We report a phase II trial of T-DM1 monotherapy in relapsed NSCLC with documented HER2 positivity (an immunohistochemistry [IHC] score of 3+, both an IHC score of 2+ and fluorescence in situ hybridization positivity, or exon 20 mutation). This study was terminated early because of limited efficacy. The demographic characteristics in the 15 assessable patients were as follows: median age, 67 years; male sex, 47%; performance status of 0 to 1, 80%; HER2 status IHC 3+, 33%; HER status IHC 2+/fluorescence in situ hybridization-positive, 20%; and exon 20 mutation, 47%. The median number of delivered cycles was 3 (range 1-11). One patient achieved a partial response with an objective response rate of 6.7% (90% confidence interval: 0.2-32.0). With a median follow-up time of 9.2 months, the median progression-free survival time and median survival time were 2.0 and 10.9 months, respectively. Grade 3 or 4 adverse events included thrombocytopenia (40%) and hepatotoxicity (20%) without any treatment-related deaths. T-DM1 had a limited efficacy for HER2-positive NSCLC in our cohort. Applying the concept of precision medicine to tumors appears challenging; thus, additional molecular approaches are warranted.

Original languageEnglish
JournalJournal of Thoracic Oncology
DOIs
Publication statusAccepted/In press - Jan 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Immunohistochemistry
Fluorescence In Situ Hybridization
Exons
TYK2 Kinase
Precision Medicine
Mutation
Survival
Thrombocytopenia
Disease-Free Survival
Demography
Confidence Intervals
Breast Neoplasms
ado-trastuzumab emtansine
Antibodies
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • HER2
  • Non-small cell lung cancer
  • Precision medicine
  • Trastuzumab emtansine

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. / Hotta, Katsuyuki; Aoe, Keisuke; Kozuki, Toshiyuki; Oohashi, Kadoaki; Ninomiya, Kiichiro; Ichihara, Eiki; Kubo, Toshio; Ninomiya, Takashi; Chikamori, Kenichi; Harada, Daijiro; Nogami, Naoyuki; Hirata, Taizo; Hinotsu, Shiro; Toyooka, Shinichi; Kiura, Katsuyuki.

In: Journal of Thoracic Oncology, 01.01.2017.

Research output: Contribution to journalArticle

@article{a9021d201bc342f0b814abb0683f785a,
title = "A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer",
abstract = "Trastuzumab emtansine (T-DM1), an anti-erb-b2 receptor tyrosine kinase 2 (HER2) antibody-drug conjugate, has been shown to significantly improve survival in HER2-positive breast cancer. We report a phase II trial of T-DM1 monotherapy in relapsed NSCLC with documented HER2 positivity (an immunohistochemistry [IHC] score of 3+, both an IHC score of 2+ and fluorescence in situ hybridization positivity, or exon 20 mutation). This study was terminated early because of limited efficacy. The demographic characteristics in the 15 assessable patients were as follows: median age, 67 years; male sex, 47{\%}; performance status of 0 to 1, 80{\%}; HER2 status IHC 3+, 33{\%}; HER status IHC 2+/fluorescence in situ hybridization-positive, 20{\%}; and exon 20 mutation, 47{\%}. The median number of delivered cycles was 3 (range 1-11). One patient achieved a partial response with an objective response rate of 6.7{\%} (90{\%} confidence interval: 0.2-32.0). With a median follow-up time of 9.2 months, the median progression-free survival time and median survival time were 2.0 and 10.9 months, respectively. Grade 3 or 4 adverse events included thrombocytopenia (40{\%}) and hepatotoxicity (20{\%}) without any treatment-related deaths. T-DM1 had a limited efficacy for HER2-positive NSCLC in our cohort. Applying the concept of precision medicine to tumors appears challenging; thus, additional molecular approaches are warranted.",
keywords = "HER2, Non-small cell lung cancer, Precision medicine, Trastuzumab emtansine",
author = "Katsuyuki Hotta and Keisuke Aoe and Toshiyuki Kozuki and Kadoaki Oohashi and Kiichiro Ninomiya and Eiki Ichihara and Toshio Kubo and Takashi Ninomiya and Kenichi Chikamori and Daijiro Harada and Naoyuki Nogami and Taizo Hirata and Shiro Hinotsu and Shinichi Toyooka and Katsuyuki Kiura",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.jtho.2017.10.032",
language = "English",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",

}

TY - JOUR

T1 - A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer

AU - Hotta, Katsuyuki

AU - Aoe, Keisuke

AU - Kozuki, Toshiyuki

AU - Oohashi, Kadoaki

AU - Ninomiya, Kiichiro

AU - Ichihara, Eiki

AU - Kubo, Toshio

AU - Ninomiya, Takashi

AU - Chikamori, Kenichi

AU - Harada, Daijiro

AU - Nogami, Naoyuki

AU - Hirata, Taizo

AU - Hinotsu, Shiro

AU - Toyooka, Shinichi

AU - Kiura, Katsuyuki

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Trastuzumab emtansine (T-DM1), an anti-erb-b2 receptor tyrosine kinase 2 (HER2) antibody-drug conjugate, has been shown to significantly improve survival in HER2-positive breast cancer. We report a phase II trial of T-DM1 monotherapy in relapsed NSCLC with documented HER2 positivity (an immunohistochemistry [IHC] score of 3+, both an IHC score of 2+ and fluorescence in situ hybridization positivity, or exon 20 mutation). This study was terminated early because of limited efficacy. The demographic characteristics in the 15 assessable patients were as follows: median age, 67 years; male sex, 47%; performance status of 0 to 1, 80%; HER2 status IHC 3+, 33%; HER status IHC 2+/fluorescence in situ hybridization-positive, 20%; and exon 20 mutation, 47%. The median number of delivered cycles was 3 (range 1-11). One patient achieved a partial response with an objective response rate of 6.7% (90% confidence interval: 0.2-32.0). With a median follow-up time of 9.2 months, the median progression-free survival time and median survival time were 2.0 and 10.9 months, respectively. Grade 3 or 4 adverse events included thrombocytopenia (40%) and hepatotoxicity (20%) without any treatment-related deaths. T-DM1 had a limited efficacy for HER2-positive NSCLC in our cohort. Applying the concept of precision medicine to tumors appears challenging; thus, additional molecular approaches are warranted.

AB - Trastuzumab emtansine (T-DM1), an anti-erb-b2 receptor tyrosine kinase 2 (HER2) antibody-drug conjugate, has been shown to significantly improve survival in HER2-positive breast cancer. We report a phase II trial of T-DM1 monotherapy in relapsed NSCLC with documented HER2 positivity (an immunohistochemistry [IHC] score of 3+, both an IHC score of 2+ and fluorescence in situ hybridization positivity, or exon 20 mutation). This study was terminated early because of limited efficacy. The demographic characteristics in the 15 assessable patients were as follows: median age, 67 years; male sex, 47%; performance status of 0 to 1, 80%; HER2 status IHC 3+, 33%; HER status IHC 2+/fluorescence in situ hybridization-positive, 20%; and exon 20 mutation, 47%. The median number of delivered cycles was 3 (range 1-11). One patient achieved a partial response with an objective response rate of 6.7% (90% confidence interval: 0.2-32.0). With a median follow-up time of 9.2 months, the median progression-free survival time and median survival time were 2.0 and 10.9 months, respectively. Grade 3 or 4 adverse events included thrombocytopenia (40%) and hepatotoxicity (20%) without any treatment-related deaths. T-DM1 had a limited efficacy for HER2-positive NSCLC in our cohort. Applying the concept of precision medicine to tumors appears challenging; thus, additional molecular approaches are warranted.

KW - HER2

KW - Non-small cell lung cancer

KW - Precision medicine

KW - Trastuzumab emtansine

UR - http://www.scopus.com/inward/record.url?scp=85038848439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038848439&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2017.10.032

DO - 10.1016/j.jtho.2017.10.032

M3 - Article

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

ER -